NY-AQARA
Aqara, a leading provider of smart home products, announced the global availability of its next-generation Matter hub, the Hub M3. Designed with a focus on edge computing, the M3 prioritizes privacy and local automation capabilities that can operate independently of internet connection or even the hub itself1. Thanks to the versatile connectivity built-in, it seamlessly integrates Aqara accessories, infrared-compatible gadgets and a number of third-party Matter devices, making it a central point for smart home automation while ensuring privacy and easy setup.
“Aqara is committed to creating the ultimate smart home experience that continuously adapts to users’ evolving needs,” said Cathy You, Aqara Senior Vice President of Global Business and Strategy. “The Hub M3's edge computing capabilities will provide users with an added layer of stability and safety, while its Matter compatibility will significantly enhance interoperability and choice for users."
Debuted at CES in January, the M3 stands out as an Edge Hub by enabling not only data privacy through end-to-end encrypted, local storage but also advanced, local automation capabilities. For Aqara users who already own an Aqara Zigbee hub, deploying a Hub M3 further strengthens the robustness of their smart home networks. Moreover, it enables more local automations between Aqara devices. Once added to the network, the M3 takes a lead over other Aqara Zigbee hubs and Wi-Fi devices, and allows automation between these devices to execute on the Edge instead of over the cloud, ensures continued functionality during internet or cloud service disruptions2. The Hub M3 also allows select Aqara Zigbee devices with Repeater functionality to act as a proxy hub and execute automations in the absence of M3. Upcoming Aqara Thread devices with Mesh Extender functionality are expected to support device binding via the M3.
As the latest evolution in Aqara’s lineup of smart home control centers, the M3 supports multiple protocols including Thread, Zigbee, Wi-Fi, Bluetooth and infrared (IR), making it a comprehensive hub for smart home management. It connects and manages the lineup of classic Aqara Zigbee devices, serving as a Matter bridge3. Thanks to the 360° IR blaster, the new hub optimizes control of IR-enabled devices by syncing their status directly with Aqara Home whenever an IR remote is utilized. Moreover, the M3 integrates the latest Aqara Thread devices as well as select Matter-compatible devices from third-party brands to Aqara Home4. This means that users can connect and manage devices from different brands and ecosystems within the Aqara Home app to ensure maximum flexibility and compatibility.
Other enhancements of the Hub M3 include:
- Matter bridge for infrared AC units: It can integrate an infrared-compatible air conditioning unit or air-to-air heat pump to Matter, allowing for AC control and automation via Matter-enabled platforms5.
- Seamless group migration: Users can easily migrate bridged device from older Aqara hubs to the M32, ensuring continuity of Aqara Home settings and automations without the need to reconfigure each device.
- Enhanced internet connectivity: The M3 features dual-band Wi-Fi (2.4GHz/5GHz) with WPA3 security as well as a PoE-enabled port, offering enhanced stability and flexibility.
- Powerful speaker: The 95dB speaker built-in can be used for home security alerts and custom announcements.
The Hub M3 is now available at Aqara’s Amazon brand stores throughout North America (US, Canada), Europe (France, Germany, Italy, Poland, Spain, UK) and Asia (Japan), as well as through select Aqara retailers worldwide.
For more information on the M3, please visit our website.
1. Some Aqara Home automation may require Internet and cloud service to function, for example, automations involve push notifications and location services (e.g., geofencing, local weather, sunrise/sunset).
2. Edge automation and group migration are not supported by the original Aqara Hub and Camera Hub G2H.
3. Not all Aqara Zigbee devices can be bridged to Matter.
4. Third-party Matter device support is limited to select brands and device types by the time of M3 launch.
5. The functionality of infrared AC units may vary depending on each particular Matter-enabled platform. Each M3 hub can bridge one infrared AC unit to Matter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508489885/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boyd Unveils a High-Capacity Coolant Distribution Unit with a 2.3 Megawatt Capacity for AI Liquid Cooling Applications8.7.2025 14:05:00 CEST | Press release
Boyd’s ROL2300 Coolant Distribution Unit Efficiently and Reliably Cools Modern High Power AI Processors in Hyperscaler, Colocation, and Enterprise Data Centers Today, Boyd announces a significant expansion of its liquid cooling product portfolio with a new high-capacity coolant distribution unit (CDU). Boyd’s new ROL2300 is a liquid-to-liquid in row system that enables high performance cooling for modern AI processor applications and is immediately available to purchase in volume. To learn more about the ROL2300, watch the video here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708530818/en/ Boyd's high capacity ROL2300 in row coolant distribution unit (CDU) efficiently and reliably cools modern high power AI processors in hyperscale, colocation, and enterprise data centers with up to a 2.3 megawatt capacity. A single ROL2300 can efficiently cool over 10 NVL72 racks. It is optimized to easily fit in data center server
Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD8.7.2025 14:00:00 CEST | Press release
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announce today that the China National Medical Products Administration (NMPA) has approved Heng Qin® (Perfluorohexyloctane Eye Drops) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708514269/en/ Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. According to the Chinese Expert Consensus on M
Esri Launches New E-Commerce Experience for Demographic Data8.7.2025 14:00:00 CEST | Press release
Organizations Can Purchase Updated, Authoritative Datasets Ranging from Census to Retail Demand To further provide individuals and organizations with the authoritative demographic data they need, Esri, the global leader in geographic information system (GIS) technology, has launched a new e-commerce experience for data in the Esri Store. A one-stop shop for enhanced, reliable information relating to people and geography, Esri’s location data store is designed to make these resources more accessible for users that rely on spatial data. “We are thrilled to launch our new e-commerce experience, making it easier than ever for customers to access the data they need to make better decisions,” said Rob Elkins, Esri director of product management. “Organizations will have access to current-year and five-year estimates for more than 2,000 demographic and socioeconomic characteristics in the US, as well as census and American Community Survey (ACS) information, consumer spending trends, market p
Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella8.7.2025 14:00:00 CEST | Press release
Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts – early immune cell clonotypes critical in the formation of neutralizing antibodies – for measles, mumps and rubella. This effort aims to build the most comprehensive understanding of the formation of neutralizing antibodies to the vaccine and to identify the dominant and effective antibodies to these infectious agents. Dr. James Crowe, Director of Vanderbilt's Center for Antibody Therapeutics, will lead the development of the large-scale immune cell study. “This collaboration enables us to create the largest single cell atlas of neutralizing plasmablasts ever assembled,” states Crowe. “By sequencing and mapping tens of millions of B cell recep
ViaLase Announces Strategic Leadership Transitions to Support Commercial Growth8.7.2025 14:00:00 CEST | Press release
ViaLase, Inc., a medical technology company pioneering noninvasive femtosecond laser treatments for glaucoma, today announced key changes to its executive leadership team as the company prepares for commercial launch and regulatory approvals in both the United States and Europe. Tibor Juhasz, PhD, founder and former Chief Executive Officer, has transitioned to the role of President and Chief Technology Officer, where he will continue to guide the company’s technological innovation roadmap. Shawn O’Neil, most recently Chief Commercial Officer, has been appointed Chief Executive Officer. In turn, Pete England has been promoted to Chief Commercial Officer. “These leadership changes mark an important milestone in ViaLase’s evolution,” said Tom Frinzi, Executive Chairman of the Board. “Tibor has done an extraordinary job building a world-class R&D and clinical organization, laying the foundation for what promises to be a major advancement in glaucoma care. His track record as an entrepreneu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom